Who
Stephen K. Doberstein
Director
Company insider
Files Form 4 as: Director, Forte Biosciences; Director, Dicerna Pharmaceuticals; SVP & Chief Scientific Officer, Nektar Therapeutics.
In numbers
- Trades disclosed
- 103
- Buys
- 1
- Sells
- 20
- Bought
- $259K
- Sold
- $30.7M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 6 Jan 2010
- Last trade
- 27 Aug 2026
- Last filed
- 27 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —31,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,353 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —31,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,353 | filing |
| 29 May 2026filed 2 Jun 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,353 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,353 at $0.00 | filing |
| 20 Mar 2025filed 21 Mar 2025 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 19 Sep 2023filed 20 Sep 2023 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Jun 2022filed 2 Jun 2022 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 12 May 2022filed 16 May 2022 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 28 Dec 2021filed 29 Dec 2021 | Dicerna Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —3,333 | filing |
News
Nektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink PartnersNKTR · tickerreport.com · 15 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink PartnersNKTR · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Stephen K. Doberstein; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.